Base Therapeutics announced that its NK510 cell injection, the world’s first zero-off-target base-edited NK cell therapy, has received Investigational New Drug (IND) approvals from the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) for clinical trials in patients with advanced solid tumors. This dual approval is a major advancement in cancer immunotherapy, showcasing Base Therapeutics’ groundbreaking base-editing technology.

NK cells are highly promising in cancer treatment due to their inherent ability to identify and eliminate cancer cells. However, NK cell-based therapies face challenges including limited expansion capabilities, resistance to genetic modification, and cancer cell immune evasion. Base Therapeutics uses its proprietary AccuBase® base-editing technology to precisely alter genes in human primary NK cells. With over 90% editing efficiency, this technology offers a safer and more effective approach to NK cell therapies. NK510 cells are designed to enhance their cancer cell targeting and overcome immune checkpoint suppression. Preclinical and clinical data demonstrate strong anti-tumor activity against solid tumors.

Furthermore, Base Therapeutics has optimized the ex vivo expansion process for NK510. Through rigorous process refinement, NK510 cells have been successfully expanded millions of times in the company’s GMP-compliant facilities, overcoming global hurdles such as low expansion and transfection rates in allogeneic NK cell products.

AccuBase® Base Editing Technology

AccuBase® is a zero-off-target base editing technology created by Base Therapeutics. Unlike traditional CRISPR methods, AccuBase® directly alters target DNA bases without causing double-strand breaks, providing a safer, more precise gene editing approach. Its successful application across diverse cell types and species has earned international recognition, including a non-exclusive license to a leading CAR-T cell therapy company.

Advantages of AccuBase®:

  • Zero-Off-Target effects due to precise design
  • Clinically validated performance
  • High efficiency without compromising cell viability, even in multiplexed gene editing
  • The world’s only GMP grade base editor with superior stability in high quality and quantity
  • The world’s only base editor deliverable as RNP
  • Global Free Trade Opportunity

About Base Therapeutics

Established in 2021, Base Therapeutics is a leading innovator in cell therapy and in vivo gene editing. The company has developed numerous base-edited therapies, including NK510 and several in vivo gene editing projects. Using its proprietary base editing technology, Base Therapeutics aims to transform cell and gene therapies globally.

For more information, visit .

For partnering inquiries, contact BD@basetherapeutics.com.